These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
143 related items for PubMed ID: 18451529
21. beta-adrenergic receptor blockade in chronic heart failure. Bristow MR. Circulation; 2000 Feb 08; 101(5):558-69. PubMed ID: 10662755 [No Abstract] [Full Text] [Related]
22. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Läer S, Mir TS, Behn F, Eiselt M, Scholz H, Venzke A, Meibohm B, Weil J. Am Heart J; 2002 May 08; 143(5):916-22. PubMed ID: 12040358 [Abstract] [Full Text] [Related]
23. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Giessmann T, Modess C, Hecker U, Zschiesche M, Dazert P, Kunert-Keil C, Warzok R, Engel G, Weitschies W, Cascorbi I, Kroemer HK, Siegmund W. Clin Pharmacol Ther; 2004 Mar 08; 75(3):213-22. PubMed ID: 15001973 [Abstract] [Full Text] [Related]
24. Carvedilol: a review of its use in chronic heart failure. Keating GM, Jarvis B. Drugs; 2003 Mar 08; 63(16):1697-741. PubMed ID: 12904089 [Abstract] [Full Text] [Related]
25. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Sehrt D, Meineke I, Tzvetkov M, Gültepe S, Brockmöller J. Pharmacogenomics; 2011 Jun 08; 12(6):783-95. PubMed ID: 21599570 [Abstract] [Full Text] [Related]
26. Carvedilol. Frishman WH. Indian Heart J; 1999 Jun 08; 51(3):325-32. PubMed ID: 10624077 [No Abstract] [Full Text] [Related]
27. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Neugebauer G, Akpan W, Kaufmann B, Reiff K. Eur J Clin Pharmacol; 1990 Jun 08; 38 Suppl 2():S108-11. PubMed ID: 1974498 [Abstract] [Full Text] [Related]
30. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Baudhuin LM, Miller WL, Train L, Bryant S, Hartman KA, Phelps M, Larock M, Jaffe AS. Am J Cardiol; 2010 Aug 01; 106(3):402-8. PubMed ID: 20643254 [Abstract] [Full Text] [Related]
35. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure. Sun YP, Wei CP, Ma SC, Zhang YF, Qiao LY, Li DH, Shan RB. J Cardiovasc Pharmacol; 2015 May 01; 65(5):480-4. PubMed ID: 25945865 [Abstract] [Full Text] [Related]
39. Rats with portacaval shunt as a potential experimental pharmacokinetic model for liver cirrhosis: application to carvedilol stereopharmacokinetics. Stahl E, Baumgartner U, Henke D, Schölmerich J, Mutschler E, Spahn-Langguth H. Chirality; 1993 May 01; 5(1):1-7. PubMed ID: 8095396 [Abstract] [Full Text] [Related]
40. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS. J Am Coll Cardiol; 2010 Apr 27; 55(17):1780-7. PubMed ID: 20413026 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]